Stock Analiz

IM Cannabis Corp. IMCC

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$0.57Market cap $1M
Open the interactive analysis →

IM Cannabis Corp. (IMCC) is a healthcare company listed in the US with a market value of about $1M. In the twelve months to March 31, 2026 it had revenue of $36M and net income of -$10M, a net margin of -27.2%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is track record (2/5); the weakest is future growth (0/5).

Key numbers: a price to free cash flow of 30.5, 5-year revenue growth of 26% a year, a 5-year average ROIC of -52%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 1760% above the current price.

About IM Cannabis

IM Cannabis is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $7M in 2019 to $40M in 2025, growth of about 33.7% a year. It was profitable in 0 of the last 7 years in our data.

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record2/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • Positive free cash flow
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF30.5
P/S0.0
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield3.3%
Shareholder yield0.0%
Intrinsic value vs. price+1760%

Growth and quality

Revenue growth (1 yr)6.4%
Revenue growth (5 yrs, per year)26.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-91.9%
ROIC (5-yr avg.)-52.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$36M$40M$38M$37M$40M$27M$12M$7M
Net income-$10M-$8M-$7M-$7M-$140M-$14M-$23M-$6M
Free cash flow$34328$3M-$856964-$7M-$10M-$31M-$8M-$6M
EPS (diluted)$-5.27$-4.48$-3.99$-3.89$-75.66$-7.58$-12.21$-3.04
Net margin-27.2%-20.7%-19.6%-19.5%-347.6%-52.2%-180.6%-80.4%
ROIC—-79.3%-45.1%-37.5%-91.2%-8.6%-58.7%-32.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is IM Cannabis stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 1760% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does IM Cannabis pay a dividend?

Not currently.

Is IM Cannabis a good stock to buy?

We do not give buy or sell advice. IM Cannabis scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.